CYTOSORBENTS CORPORATION (CTSO) Total liabilities 2016–2025
CYTOSORBENTS CORPORATION (CTSO) total liabilities at each fiscal year-end, per SEC filings.
$38.3MFY2025 · since FY2016: $8.4M → $38.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $38.3M | +5.6% |
| FY2024 | $36.3M | +23.0% |
| FY2023 | $29.5M | +5.8% |
| FY2022 | $27.9M | +3.4% |
| FY2021 | $26.9M | +151.0% |
| FY2020 | $10.7M | -55.2% |
| FY2019 | $24.0M | +38.8% |
| FY2018 | $17.3M | +24.7% |
| FY2017 | $13.8M | +65.6% |
| FY2016 | $8.4M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More CTSO financial trends
CTSO RevenueCTSO Net incomeCTSO Net marginCTSO Gross profitCTSO Gross marginCTSO Operating incomeCTSO Operating marginCTSO Operating cash flowCTSO Free cash flowCTSO Capital expendituresCTSO Return on equityCTSO Stock buybacksCTSO Dividends paidCTSO Total assetsCTSO Shareholders’ equityCTSO overview →